Skip to main content

Table 1 Published CIK cell clinical studies

From: Cytokine-induced killer cells promote antitumor immunity

Year

Tumor type

No. of cases

Culture condition

Authors

1999

Renal cell carcinoma Colorectal carcinoma Lymphoma

10

IFN-γ, anti-CD3, IL2 plus IL-2 transgene

Schmidt-Wolf IG et al. [33]

2005

Lymphoma

9

IFN-γ, anti-CD3, and IL2

Leemhuis T et al. [14]

2006

Gastric carcinoma

57

IFN-γ, anti-CD3, IL2 and IL-1alpha

Jiang JT et al. [34]

2007

Leukemia

11

IFN-γ, anti-CD3 and IL2

Introna M et al. [35]

2008

Non-small cell lung cancer

59

IFN-γ, anti-CD3, IL2 and IL-1alpha

Wu CP et al. [36]

2009

Hepatocellular carcinoma

127

IFN-γ, anti-CD3, IL2 and IL-1lalpha

Hui D et al. [37]

2009

Renal cell carcinoma and lymphoma

6

IFN-γ, anti-CD3, and IL2

Olioso P et al. [38]

2010

Gastric carcinoma

156

IFN-γ, anti-CD3, IL2, and IL-1alpha

Jiang JT et al. [39]

2011

relapsed hematologic malignancies

18

IFN-γ, anti-CD3, and IL2

Laport GG et al. [40]

2012

Renal cell carcinoma

74

IFN-γ, anti-CD3, IL2, IL-1beta

Liu L et al. [41]